Search Results for: "Other News to Note"
-
Other News To Note
Trimel Pharmaceuticals Corp., of Toronto, said it submitted a new drug application to the FDA for approval of its bioadhesive intranasal gel testosterone product, indicated for the treatment of testosterone deficiency in menBioWorld Today | Wednesday, May 1, 2013 -
Other News To Note
In exchange, Acorda will pay NeurogesX $7 million upon closing and up to an additional $5 million in post-closing milestone payments: $2 million upon FDA approval of NGX-1998 prior to Dec. 31, 2016, and $3 million if net sales of NGX-1998 in Acorda's territory (which excludes Europe, Africa and the Middle East) reach $100 million during the first 12 months on the marketBioWorld Today | Friday, April 19, 2013 -
Pharma: Other News To Note
filed suit against Actavis in U.S. District Court for the District of Delaware to prevent Actavis from commercializing the product, resulting in a stay of final FDA approval of Actavis's ANDA for up to 30 monthsBioWorld Today | Tuesday, April 2, 2013 -
Other News To Note
Stivarga won FDA approval last year. (See BioWorld Today, Sept. 28, 2012BioWorld Today | Wednesday, March 27, 2013 -
Pharma: Other News To Note
Xeljanz gained FDA approval last year. (See BioWorld Today, Nov. 8, 2012BioWorld Today | Wednesday, March 27, 2013 -
Other News To Note
Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assaysBioWorld International | Wednesday, March 13, 2013 -
Other News To Note
Dako, of Glostrup, Denmark, part of Agilent Technologies Co., received FDA approval for the addition of Kadcyla (ado-trastuzumab emtansine) to the labeling of two Dako companion diagnostic assaysBioWorld Today | Wednesday, March 6, 2013 -
Pharma: Other News To Note
The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivitiesBioWorld Today | Monday, March 4, 2013 -
Other News To Note
Pending FDA approval, the company intends to initiate a Phase II study in late 2013 or early 2014. (See BioWorld Today, Feb. 15, 2011, and Oct. 29, 2012BioWorld Today | Monday, March 4, 2013 -
Pharma: Other News To Note
Baxter International Inc., of Deerfield, Ill., said it submitted a biologics license application supplement to the FDA for approval of prophylaxis treatment of FEIBA NF (anti-inhibitor coagulant complex), nanofiltered and vapor-heated, in patients with hemophilia A or B and inhibitorsBioWorld Today | Wednesday, February 27, 2013 -
Other News To Note
He pegged the odds of FDA approval at less than 50 percent, but added "there is now the opportunity for a major upside surprise that did not exist previouslyBioWorld Today | Friday, February 15, 2013 -
Other News To Note
Vascepa gained FDA approval last yearBioWorld International | Wednesday, January 30, 2013 -
Other News To Note
QRxPharma Ltd., of Sydney, Australia, said it clarified the steps necessary with the FDA for approval of pain candidate MoxDuo, with a new drug application resubmission expected this quarter and a new PDUFA date set for the third quarterBioWorld International | Wednesday, January 23, 2013 -
Other News To Note
QRxPharma Ltd., of Sydney, Australia, said it clarified the steps necessary with the FDA for approval of pain candidate MoxDuo, with a new drug application resubmission expected this quarter and a new PDUFA date set for the third quarterBioWorld Today | Thursday, January 17, 2013 -
Pharma: Other News To Note
6,545,040, or the date Glenmark receives final FDA approval of its ANDABioWorld Today | Friday, January 4, 2013 -
Other News To Note
The sNDA requests FDA approval to expand the indication for ferumoxytol beyond the current indication for the treatment of iron deficiency anemia (IDA) in adult patients with chronic kidney disease to all adult patients with IDA who have failed or could not tolerate oral iron treatmentBioWorld Today | Thursday, December 27, 2012 -
Other News To Note
The FDA approval was based on a clinical data package involving more than 1 ,600 patients and subjectsBioWorld Today | Wednesday, December 26, 2012 -
Other News To Note
Sucampo Pharmaceuticals Inc., of Bethesda, Md., received FDA approval of an supplemental new drug application for Rescula (unoprostone isopropyl ophthalmic solution) for the lowering of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertensionBioWorld Today | Thursday, December 13, 2012 -
Other News To Note
Brinavess has received approval in the European Union for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults but has not received FDA approval...Somaxon gained FDA approval of insomnia product Silenor but has struggled to gain traction in the commercial market, despite a U.SBioWorld Today | Wednesday, December 12, 2012 -
Other News To Note
The news came late Thursday, shortly after the company disclosed FDA approval of Cometriq in MTCBioWorld Today | Monday, December 3, 2012
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.